Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Our lead product is our patented AVERSA platform technology. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiS use and Accidental exposure of drugs with abuse potential, specifically Opioids. Our first application for AVERSA is for our abuse deterrent fentanyl transdermal patch which we are developing with Kindeva Drug Delivery to provide clinicians and patients with an extended release chronic pain relief patch. The goal is to drastically reduce the ability to abuse certain pain treatments while simultaneously making these treatments available again to patients who have had their access cut due to the negative stigma associated with certain opioids.
Nutriband is one of the many featured companies slated to present at The Microcap Conference 2024, set for Jan. 30-Feb. 1 at Caesars Atlantic City Hotel and Casino. This three-day conference presented by DealFlow Events features technical programming designed for microcap investors and a presenting company track for pitching and socializing.
History of the company’s formation
Formed in 2016 by Gareth Sheridan (CEO) and Serguei Melnik (Chairman), the company spent a number of years acquiring smaller transdermal companies such as 4P Therapeutics, which is now Nutriband’s Clinical Research arm, as well as Pocono Pharmaceutical, now the company’s contract manufacturing subsidiary.
In October 2021 Nutriband listed on the Nasdaq under the symbol NTRB where it has been trading since.
AVERSA Fentanyl which is the first application for the company’s technology is estimated by Health Advances to reach peak annual sales of $80 million – $200 million. As of 2024 Nutriband is targeting an FDA submission before fiscal year end.
Key leadership and accomplishments
Dr. Alan Smith, Nutriband’s COO and president of the 4P Therapeutics subsidiary, was selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee in March 2023
Nutriband was nominated for 5 awards at the 2023 Pharmaceutical Industry Awards:
- Small / Medium Pharma Company of the Year
- Pharma Project of the Year – AVERSA
- Innovation of the Year – AVERSA
- Research and Development Achievement Award
- Product Impact Award – AVERSA
Looking to the future
An FDA submission before the end of Nutriband’s fiscal year end is the company’s primary target this year. Nutriband has mostly completed a feasibility study with Kindeva Drug Delivery and recently announced the signing of a Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery For Aversa™ Fentanyl, an Abuse Deterrent Fentanyl Patch. As Nutriband progresses in the near term, they will be initiating Pre IND and IND meetings with the FDA, working to start and complete a Human Abuse Liability Study and striving to submit to the FDA for review before year end.
Tickets are going fast for the inaugural Microcap Conference 2024. Reserve your seat now for unsurpassed networking and technical discussions of the microcap sector with some of the best names in the business – institutional investors, finance-focused law firms, venture and private equity fund managers, deal advisors, PIPE funds, brokerage firms, investor relations professionals, accredited retail investors and many more. The conference schedule is also packed with entertainment and exciting activities set against the backdrop of Atlantic City’s bright lights.
Sponsored content, this is a paid promotion
Comments and opinions presented in DealFlow Events publications such as The Microcap Newsletter are solely those of the analysts, corporate executives, and others quoted. They do not represent the opinions of DealFlow Events and DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter.